Maternal Use of Dermatologic Drugs and Infant Congenital Malformations
Most dermatologic drugs are used topically. Some of these have been linked to a teratogenic risk but according to modern literature this seems to be unlikely which is supported by new data for some of the most commonly used such drugs, e.g., topical corticosteroids. Topically used retinoids (e.g., tretinoin) should be avoided during pregnancy but presently available data do not suggest a marked teratogenic risk. Systemic use of retinoids (notably isotretinoin) should be avoided during pregnancy. If such exposure has occurred, interruption of pregnancy should be considered.
- Chi CC, Wang SH, Wojnarowska F, Kirtshig G, Davies E, Bennet C. Safety of topical steroids in pregnancy. Cochrane Database Syst Rev. 2015;(10):CD007346. https://doi.org/10.1002/14651858.CD007346.pub3.
- Källén B. Drugs during pregnancy. New York: Nova Biomedical Books; 2009. p. 172.Google Scholar
- Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet. 2005;136A:117–21.CrossRefGoogle Scholar
- Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Stahl B, Rousso P, Winterfeld U, Rothuizen LE, Buclin T. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52:1844–51.CrossRefGoogle Scholar